FIT Biotech Oy
Company release August 16, 2018 at 04:15 PM EET
FIT Biotech Oy’s Board of Directors has decided on the issue of Convertible Notes and Warrants
On December 22, 2017, the Board of Directors of FIT Biotech Oy (hereinafter also the “Company”) decided to establish Convertible Note and Warrant Programmes in order to implement the Convertible Notes with Warrants Funding Programme of up to EUR 10,000,000 between the Company and Alpha Blue Ocean of the same date. The Extraordinary General meeting approved the financing Programme on February 6, 2018.
The Company’s Board of Directors decided on August 16, 2018 to draw down the sixth tranche of EUR 500,000 included in the Programme and to issue to ABO a total of 500 Convertible Notes and 750,000,000 Warrants, which entitle to subscribe for the Company’s K shares in accordance with the Characteristics of the Warrants.
FIT BIOTECH OY
Board of Directors
For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
NASDAQ OMX Helsinki